Arvinas Reports 91.7% Revenue Decline in Q1 2026, Net Loss of $57.6 Million

Arvinas, Inc. reported a significant decline in financial performance for the first quarter of 2026, with revenues totaling $15.6 million, a decrease of 91.7% from $188.8 million in the same period of 2025. This drop was primarily attributed to a reduction in revenue from the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer, which saw a decrease of $175.6 million due to changes in program cost estimates following the removal of two Phase 3 trials from the development plan. In contrast, revenue from the Pfizer Research Collaboration Agreement increased by $2.3 million due to adjustments in performance period estimates.

Operating expenses also decreased, with total operating expenses for the quarter amounting to $79.4 million, down from $117.4 million in the prior year. Research and development expenses fell to $60.3 million from $90.8 million, reflecting a reduction in compensation and related personnel expenses, as well as external program-specific expenses. General and administrative expenses decreased to $19.1 million from $26.6 million, primarily due to lower professional fees and costs associated with developing commercial operations. Despite these reductions, the company reported a net loss of $57.6 million, compared to a net income of $82.9 million in the previous year.

Strategically, Arvinas announced the FDA approval of VEPPANU™ (vepdegestrant) for the treatment of advanced or metastatic breast cancer, marking a significant milestone as it is the first FDA-approved PROTAC protein degrader. The company is collaborating with Pfizer to select a third party for the commercialization and further development of VEPPANU. Additionally, Arvinas is advancing several other product candidates through clinical development, including ARV-102, ARV-806, ARV-393, and ARV-027, targeting various oncology and neurology indications.

As of March 31, 2026, Arvinas had cash, cash equivalents, and marketable securities totaling approximately $614.9 million, which the company believes will be sufficient to fund operations into the second half of 2028. However, the company continues to face significant operating losses and anticipates the need for additional funding to support ongoing and future clinical trials. The outlook remains cautious, with the company emphasizing the uncertainty surrounding the timing and success of its product development efforts and the potential for future revenue generation.